Evolus, Inc. (NASDAQ:EOLS – Get Free Report) insider David Moatazedi sold 116,720 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total value of $570,760.80. Following the completion of the sale, the insider owned 618,369 shares of the company’s stock, valued at approximately $3,023,824.41. This trade represents a 15.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
David Moatazedi also recently made the following trade(s):
- On Monday, December 22nd, David Moatazedi sold 10,539 shares of Evolus stock. The shares were sold at an average price of $7.15, for a total value of $75,353.85.
Evolus Stock Up 0.6%
NASDAQ:EOLS opened at $4.86 on Friday. The business’s 50-day moving average price is $4.81 and its 200 day moving average price is $6.08. The firm has a market cap of $316.19 million, a P/E ratio of -6.00 and a beta of 1.02. Evolus, Inc. has a 52-week low of $4.09 and a 52-week high of $13.66.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on the company. HC Wainwright cut their price objective on Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Needham & Company LLC restated a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. Wall Street Zen cut shares of Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. Finally, Stifel Nicolaus reduced their price objective on shares of Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $16.00.
Check Out Our Latest Stock Report on EOLS
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP acquired a new position in Evolus in the 4th quarter worth about $545,000. Alpine Global Management LLC bought a new stake in Evolus in the fourth quarter worth approximately $173,000. Virtu Financial LLC acquired a new position in shares of Evolus during the 4th quarter valued at $151,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Evolus during the 4th quarter worth about $144,000. Finally, Wellington Management Group LLP grew its position in Evolus by 5.9% in the 4th quarter. Wellington Management Group LLP now owns 195,160 shares of the company’s stock valued at $1,298,000 after purchasing an additional 10,850 shares during the period. Institutional investors and hedge funds own 90.69% of the company’s stock.
Evolus Company Profile
Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.
The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.
Further Reading
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
